Testosterone Therapy Passed Its Heart Test. That Doesn't Mean You Need It

Two true things are sitting side by side in the testosterone conversation, and they keep getting merged into one false thing.

The first is that a large, well-run trial found testosterone replacement did not raise the rate of major heart events in men with diagnosed low testosterone. The second is that a large share of men being prescribed it were never properly diagnosed in the first place. Reassuring safety data does not repair a shaky diagnosis. It only means that if the diagnosis is right, one particular fear is smaller than we thought.

What TRAVERSE Actually Tested

TRAVERSE was a randomized, placebo-controlled trial, led from the Cleveland Clinic and published in the New England Journal of Medicine. It enrolled just over five thousand men, roughly 45 to 80 years old, who had symptoms of low testosterone, blood levels confirming it, and either existing cardiovascular disease or a high risk of it. They were assigned to a daily testosterone gel or a placebo gel and followed for a median of nearly three years.

The question was narrow and important: does replacing testosterone in these men raise the rate of heart attack, stroke or cardiovascular death? The answer, in the published primary analysis, was that it did not. Event rates were close to identical, a bit over seven percent in each group, and the trial met its statistical bar for non-inferiority.

That is a real result. For years the field carried an unresolved worry, fed by earlier smaller studies that pointed in different directions. TRAVERSE was designed to settle it for exactly the population most likely to be harmed, and for that population it was reassuring.

What It Did Not Test

This is where the headline stretches past the data.

Men with normal testosterone. Everyone enrolled had confirmed low levels. The trial says nothing about whether men in the normal range gain anything, or whether they are safe doing it.
Every possible harm. The heart result was reassuring, but men on testosterone in the trial had more atrial fibrillation, acute kidney injury and pulmonary embolism than men on placebo. A later analysis of fractures also reported a slight increase in the testosterone group. These were not the primary question, but they are part of the same dataset.
Other forms and doses. The trial used a gel at a specific dosing approach, with monitoring. Injections, pellets and compounded products are not the same exposure.
Long-term outcomes beyond a few years. Follow-up was a few years, not decades.

Researchers who ran the trial have been explicit that the result should not be read as a green light for broad prescribing. It answers a safety question for a defined group. It does not make the treatment appropriate for everyone who feels tired.

The Overprescribing Problem

The more worrying signal came from a different direction. Work presented at the ENDO 2026 meeting looked at men who had been prescribed testosterone and found that many had not had the guideline-concordant diagnostic testing beforehand. I am reading that from the conference report rather than a full paper, so treat the specifics with care. The shape of it is not new, though, and it matches what clinicians have been saying for years.

Guideline-concordant testing looks like this, in plain terms:

Symptoms that fit, assessed first. Not a lab value hunting for a symptom.
A fasting morning total testosterone, because levels are highest early and drift down through the day.
A second morning measurement on a different day, because a single value is noisy and can be low from a bad night, an acute illness, or lab variation.
A clearly low result on both, using the lab's threshold. Many guidelines and TRAVERSE itself used about 300 ng/dL as the cut-off.
A look at why. Obesity, sleep apnea, opioids, poorly controlled diabetes and several other conditions lower testosterone, and treating them can raise it without a prescription.

Skip any of those steps and you may be treating a number that would have corrected itself, or a symptom that belongs to something else.

Clinically Low Testosterone Versus Ordinary Aging

Testosterone does decline gradually with age, on average. That is different from hypogonadism, which is a medical condition where levels are persistently below the normal range and produce a recognizable set of symptoms.

The symptoms that point more specifically toward low testosterone are reduced sexual desire, fewer spontaneous morning erections, erectile difficulty, and sometimes loss of muscle mass and body hair or hot flushes. The symptoms people most often attach to it are fatigue, low mood, poor concentration, weight gain and a general sense of flatness. These are real, but they are also what poor sleep, depression, thyroid problems, stress and plain overwork produce. They do not discriminate.

Marketing of "low T" works by borrowing the second list and implying the first.

What the Telehealth Boom Often Gets Wrong

The direct-to-consumer model makes access easier, and for some men that is a genuine improvement. People with real symptoms who were dismissed in a rushed appointment now have a route.

The weakness is structural. When a service earns money by prescribing, and the visit is a form plus a single lab draw, the incentives lean toward a yes. Repeat testing, investigating causes, discussing fertility and arranging follow-up bloodwork all cost time. Testosterone therapy suppresses sperm production, which matters for any man who might want children. It can raise red blood cell counts, which needs monitoring. It can worsen untreated sleep apnea. None of that is a reason to refuse it to men who need it. It is a reason for the workup to be done properly first.

Who Genuinely Benefits

For men over 65 with confirmed low testosterone, the best evidence comes from the Testosterone Trials, also published in NEJM. Treatment improved sexual function and desire, and produced modest improvements in mood and some measures of vitality. Physical function results were more mixed, and the effect on walking distance was not impressive. Later results from TRAVERSE showed a similar modest gain in sexual function.

That is a meaningful benefit for the right person. It is also a modest one, which is worth knowing before committing to what is often an open-ended treatment.

A Checklist Before You Ask for a Prescription

This is not a diagnostic tool. It is a way of arriving at the appointment better prepared.

Symptoms worth a proper workup, especially if several cluster for more than a few months:

Noticeably lower sexual desire than your own baseline
Fewer morning erections, or new difficulty with erections
Unexplained loss of muscle or strength despite training
Persistent low energy that does not improve with sleep
Reduced body or facial hair, or hot flushes

Things that more often reflect ordinary life than testosterone:

Tiredness that tracks with short or broken sleep
Low mood that came after a stressful stretch
Weight gain around the middle that came with years of desk work
A single borderline blood value from one afternoon draw

Questions to ask before accepting a prescription:

Have I had two separate fasting morning measurements, and what were the numbers?
What else could be producing these symptoms, and has that been checked?
Are sleep apnea, weight, medications or diabetes involved?
How will you monitor red blood cell count, PSA where appropriate, and my symptoms?
What happens to fertility, and what is the plan if I want children?
When would we stop if I do not see a benefit?

FAQ

Does TRAVERSE mean testosterone therapy is safe for everyone?

No. It showed no increase in major heart events in men with confirmed low testosterone and elevated cardiovascular risk. It did not test men with normal levels, and other risks showed up in secondary results.

Can lifestyle changes raise testosterone?

In men with obesity, weight loss tends to raise testosterone, and treating sleep apnea or improving sleep can help. Results vary, which is why trying those first, with a proper diagnosis, is often reasonable.

Why morning blood draws?

Testosterone follows a daily rhythm, highest in the early morning. A mid-afternoon reading can look low in a man whose morning level is normal.

Is a normal level the same as a healthy level?

Not necessarily, and that is part of the confusion. Reference ranges are wide, and a number inside the range can still be low for you. That is why symptoms and repeated measurements both matter, and why this is a conversation with a clinician, not a calculation.

This article is general information and not medical advice. A trial that clears a treatment of one specific danger is good news. It is just the beginning of the question of whether it is for you.